Perrine Martin, et al. Journal of Hepatology, 2013, (58), Supplement 1, S57–S58. – Download the article Publication
Catégorie : dates
Phase II trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, followed by sorafenib in patients with advanced hepatocellular carcinoma (HCC)
link J. Heo, C. Breitbach, M. Cho, T.H. Hwang, C.W. Kim, U.B. Jeon, H.Y. Woo, K.T. Yoon, J.W. Lee, J. Burke, T. Hickman, K. Dubois, L. Longpre, R. Patt, D.H. Kirn Journal of clinical Oncology, 2013, 31, (suppl; abstr 4122) [Publication]
Phase Ib dose-escalation study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, administered by intravenous (IV) infusions in patients with metastatic colorectal carcinoma (mCRC)
link J. Lee J, S.Y. Park, J. Burke, H.Y. Lim, J. Lee, W.K. Kang, J.O. Park, A. Pelusio, C. Breitbach, D.H. Kirn Journal of clinical Oncology, 2013, 31, (suppl; abstr 3608) [Publication]
Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans
Mi Kyung Kim, et al. Science Translational Medicine. 2013 May 15;5(185):185ra63 – Download the article Publication
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
Jeong Heo, et al. Nature Medicine, 2013 (3):329-36. doi: 10.1038/nm.3089. Epub 2013 Feb 10. – Download the article Publication
Therapeutic cancer vaccines in the treatment of non-small cell lung cancer
Jean-Marc Limacher, et al. Expert Review of Vaccines, 2013; 12(3): 263-270 – Download the article Publication
